Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer. (nature.com)

Authors: Mahadevan KK … Kalluri R Journal: Nature Communications Published: 2026-07-27 DOI: https://doi.org/10.1038/s41467-026-75960-3